Know Cancer

or
forgot password

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients


N/A
30 Years
85 Years
Open (Enrolling)
Male
Cachexia

Thank you

Trial Information

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients


Inclusion Criteria:



- male

- 30-85 years

- Body Mass Index (BMI) <30 kg/m2

Exclusion Criteria:

- Uncontrolled hypertension

- Glomerular filtration rate less than 60 mL/min/1.73 m2

- History of recurrent gastrointestinal bleeding

- Unable or unwilling to provide informed consent

- Ongoing anti-coagulant therapy

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Assessment of the slope of terminal D-3MH/3MH decay curve post-dosing.

Outcome Description:

Assess the slope of the terminal D-3MH/3MH decay curve for the post-dosing time period as calculated using plasma or urine samples and after a meat-containing or meat-free test meal.

Outcome Time Frame:

Post-dosing 12 to 22 hours

Safety Issue:

No

Principal Investigator

Melinda Sheffield-Moore, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Texas

Authority:

United States: Institutional Review Board

Study ID:

09-150B

NCT ID:

NCT00994669

Start Date:

October 2009

Completion Date:

June 2015

Related Keywords:

  • Cachexia
  • Cachexia

Name

Location

University of Texas Medical BranchGalveston, Texas  77555-1329